Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of real-world data, how ‘big data’ can help physicians understand treatment characteristics, and the future impact of incorporating this data into management of multiple sclerosis.
1. Randomized controlled trials are the gold standard for supporting the approval of interventions; what benefits are gained when exploring real-world data for the impact of treatments? (00:15)
2. How can ‘big data’ help physicians understand treatment characteristics in the population of people with multiple sclerosis, and what do you think the most important signals are? (00:56)
3. What evidence exists to support physicians in deciding when to initiate, switch or cease a pharmaceutical intervention? (01:34)
4. What do you see as the future impact of incorporating more real-world data into the understanding of management of multiple sclerosis? (02:26)
The abstract titled ‘Real-World-Evidence (Big data, registries): “game-changer” for regulatory and clinical views on when to start, switch and stop of disease-modifying therapies in MS?’ (Abstract #SYMP02-4) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Melinda Magyari has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
Click here for more content on this topic.
Share this Video
Related Videos In Multiple Sclerosis
Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the aim, designs and outcomes of these studies as well as the subpopulation analyses […]
Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the unmet needs of this population and the mechanism of action of ublituximab. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!